Serum Interleukin-6 as a predictor of in-hospital events in patients with acute decompensated heart failure
Main Article Content
Abstract
Systemic inflammation plays a central role in the pathophysiology of acute decompensated heart failure, in which Interleukin-6 is an important proinflammatory cytokine; however, data on the short-term prognostic value of this biomarker remain limited. This descriptive cross-sectional study with longitudinal follow-up included 70 patients with acute decompensated heart failure; the purpose of the study was to evaluate the value of serum Interleukin-6 in predicting in-hospital events at Tay Ninh General Hospital. The results showed that 12.9% of patients experienced in-hospital events, including 10.0% requiring mechanical ventilation and 2.9% in-hospital mortality. Interleukin-6 levels were significantly higher in patients with events than in those without events, with median levels of 303.80 pg/mL and 11.70 pg/mL, respectively (p < 0.001). Interleukin-6 demonstrated good discriminative ability for in-hospital events, with an AUC of 0.891, which was higher than that of NT-proBNP (AUC = 0.818). At a cutoff value of 56.8 pg/mL, Interleukin-6 yielded a sensitivity of 88.9%, specificity of 80.3%, positive predictive value of 40.0%, and negative predictive value of 98.0%. These findings suggest that serum Interleukin-6 may serve as a useful biomarker to support risk assessment for in-hospital events in patients with acute decompensated heart failure.
Article Details
Keywords
acute decompensated heart failure, interleukin-6, in-hospital adverse events, intensive care unit, prognosis
References
2. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44(37):3627-3639. doi: 10.1002/ejhf.3024.
3. Michou E, Wussler D, Belkin M, et al. Quantifying inflammation using interleukin-6 for improved phenotyping and risk stratification in acute heart failure. Eur J Heart Fail. 2023;25(2):174-184. doi: 10.1002/ejhf.2767.
4. Mooney L, Jackson CE, Adamson C, et al. Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2023;16(4):e010051. doi: 10.1161/circheartfailure.122.010051.
5. Nguyễn Quang Trung, Nguyễn Hoàng Anh, Đinh Tấn Quỳnh, Nguyễn Hoàng Hải. Đặc điểm và kết cục ngắn hạn của người bệnh nhập viện vì suy tim mất bù cấp tại Bệnh viện Nhân dân Gia Định. Tạp chí Y học Việt Nam. 2024;542(3). doi: 10.51298/vmj.v542i3.11213.
6. De Matteis G, Covino M, Burzo ML, et al. Clinical characteristics and predictors of in-hospital mortality among older patients with acute heart failure. J Clin Med. 2022;11(2). doi: 10.3390/jcm11020439.
7. Perez AL, Grodin JL, Chaikijurajai T, et al. Interleukin-6 and outcomes in acute heart failure: an ASCEND-HF substudy. J Card Fail. 2021;27(6):670-676. doi: 10.1016/j.cardfail.2021.01.006.
8. Suzuki H, Sato R, Sato T, et al. Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. Int J Cardiol. 2005;100(3):415-20. doi: 10.1016/j.ijcard.2004.08.041.
9. Chin BS, Conway DS, Chung NA, et al. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14(6):515-21. doi: 10.1097/00001721-200309000-00001.
10. Mehta NN, deGoma E, Shapiro MD. IL-6 and Cardiovascular Risk: A Narrative Review. Curr Atheroscler Rep. 2024;27(1):12. doi: 10.1007/s11883-024-01259-7.
11. Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49(3):264-8. doi: 10.1016/j.cyto.2009.11.006.
12. Orús J, Roig E, Perez-Villa F, et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant. 2000;19(5):419-25. doi: 10.1016/s1053-2498(00)00083-8.
13. Chirino Navarta DA, Trejo G, Leonardi MS, et al. Usefulness of interleukin-6 and high-sensitivity C-reactive protein as prognostic markers in outpatients with heart failure and reduced ejection fraction. Rev Argent Cardiol. 2020;88(3):190-196. doi: 10.7775/rac.v88.i3.17251.
14. Pudil R, Tichý M, Andrýs C, et al. Plasma interleukin-6 level is associated with NT-proBNP level and predicts short- and long-term mortality in patients with acute heart failure. Acta Medica 2010;53(4):225-8. doi: 10.14712/18059694.2016.81.